Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
A study on patients who are hospitalized and tested positive for COVID-19 or have a typical CT image of COVID-19 infection, to establish if omega-3 Polyunsaturated Fatty Acid (PUFA) supplementation by intravenous route is a possible treatment option in COVID-19 with minimal risks to the patients.
Description: white blood cell counts
Measure: Changes in inflammatory biomarkers Time: 5 daysDescription: CRP
Measure: Changes in inflammatory biomarkers Time: 5 daysDescription: lipidomic profiling
Measure: Changes in inflammatory biomarkers Time: 5 daysDescription: cytokines
Measure: Changes in inflammatory biomarkers Time: 5 daysDescription: metabolomic profiling
Measure: Changes in inflammatory biomarkers Time: 5 daysDescription: lipidomics
Measure: Changes in proresolving mediators Time: 5 daysDescription: fatty acid profile
Measure: Changes in fatty acids in the erythrocyte fraction Time: 5 daysDescription: Troponin, NTproBNP
Measure: Changes in cardiac biomarkers Time: 5 daysDescription: LD, creatinine
Measure: Changes in biomarkers of organ damage Time: 5 daysDescription: platelet count, D-dimer,
Measure: Changes in thrombosis parameters Time: 5 daysDescription: fibrinogen
Measure: Changes in coagulation parameters Time: 5 daysDescription: procalcitonin concentrations
Measure: Changes in markers of infection Time: 5 daysDescription: SARS-CoV2-RNAemia
Measure: Changes in infection load Time: 5 daysDescription: National Early Warning Score (NEWS2)
Measure: Changes in clinical parameters Time: through study completion, on average 10 daysDescription: Days of hospital stay
Measure: Length of hospital stay Time: through study completion, on average 10 daysDescription: ICU need, mortality
Measure: Complications Time: through study completion, on average 10 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports